Colleen Kusy
Stock Analyst at Baird
(0.64)
# 3,796
Out of 4,842 analysts
44
Total ratings
20.51%
Success rate
-20.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGEN Agenus | Maintains: Neutral | $3 → $4 | $3.02 | +32.45% | 3 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $55 → $47 | $16.80 | +179.76% | 11 | May 8, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.66 | +108.60% | 4 | Mar 13, 2025 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $4 → $6 | $0.80 | +650.84% | 5 | Dec 5, 2024 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $16.01 | +149.84% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.09 | +330.89% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.37 | +719.90% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $7.89 | +115.46% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $5.97 | +318.76% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $71.43 | +47.00% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.48 | +4,587.50% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.75 | +1,842.86% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.76 | +12,968.18% | 1 | Nov 2, 2021 |
Agenus
May 13, 2025
Maintains: Neutral
Price Target: $3 → $4
Current: $3.02
Upside: +32.45%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Outperform
Price Target: $55 → $47
Current: $16.80
Upside: +179.76%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.66
Upside: +108.60%
Coherus BioSciences
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.80
Upside: +650.84%
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $16.01
Upside: +149.84%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.09
Upside: +330.89%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.37
Upside: +719.90%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $7.89
Upside: +115.46%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $5.97
Upside: +318.76%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $71.43
Upside: +47.00%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.48
Upside: +4,587.50%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.75
Upside: +1,842.86%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.76
Upside: +12,968.18%